
Nandita M Desouza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9207802/publications.pdf Version: 2024-02-01



NANDITA M DESOUZA

#	Article	IF	CITATIONS
1	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
2	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncology, The, 2020, 21, e18-e28.	10.7	588
3	Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging, 2006, 6, 135-143.	2.8	293
4	Metastatic Ovarian and Primary Peritoneal Cancer: Assessing Chemotherapy Response with Diffusion-weighted MR Imaging—Value of Histogram Analysis of Apparent Diffusion Coefficients. Radiology, 2011, 261, 182-192.	7.3	211
5	Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. European Journal of Cancer, 2018, 91, 153-163.	2.8	107
6	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	10.7	98
7	Diffusion-weighted Imaging of Peritoneal Disease for Noninvasive Staging of Advanced Ovarian Cancer. Radiographics, 2010, 30, 1269-1285.	3.3	94
8	Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial. Scientific Reports, 2019, 9, 4800.	3.3	93
9	New MR Techniques in Gynecologic Cancer. American Journal of Roentgenology, 2013, 200, 249-260.	2.2	74
10	Cervical cancer: Value of an endovaginal coil magnetic resonance imaging technique in detecting small volume disease and assessing parametrial extension. Gynecologic Oncology, 2006, 102, 80-85.	1.4	70
11	Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. European Journal of Cancer, 2012, 48, 425-431.	2.8	68
12	Diffusion-Weighted MRI for Locally Recurrent Prostate Cancer After External Beam Radiotherapy. American Journal of Roentgenology, 2012, 198, 596-602.	2.2	64
13	Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Into Imaging, 2019, 10, 87.	3.4	61
14	Modelling DW-MRI data from primary and metastatic ovarian tumours. European Radiology, 2015, 25, 2033-2040.	4.5	57
15	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	4.5	53
16	Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability. European Radiology, 2017, 27, 4552-4562.	4.5	46
17	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology, 2017, 284, 88-99.	7.3	45
18	A framework for optimization of diffusion-weighted MRI protocols for large field-of-view abdominal-pelvic imaging in multicenter studies. Medical Physics, 2015, 43, 95-110.	3.0	33

#	Article	IF	CITATIONS
19	Investigation of metabolite changes in the transition from preâ€invasive to invasive cervical cancer measured using ¹ H and ³¹ P magic angle spinning MRS of intact tissue. NMR in Biomedicine, 2009, 22, 191-198.	2.8	30
20	Radiomic features of cervical cancer on T2-and diffusion-weighted MRI: Prognostic value in low-volume tumors suitable for trachelectomy. Gynecologic Oncology, 2020, 156, 107-114.	1.4	29
21	Development of a temperatureâ€controlled phantom for magnetic resonance quality assurance of diffusion, dynamic, and relaxometry measurements. Medical Physics, 2016, 43, 2998-3007.	3.0	26
22	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology, 2019, 293, 374-383.	7.3	25
23	Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. European Radiology, 2016, 26, 941-950.	4.5	24
24	Preoperative imaging in patients undergoing trachelectomy for cervical cancer: Validation of a combined T2- and diffusion-weighted endovaginal MRI technique at 3.0T. Gynecologic Oncology, 2014, 133, 326-332.	1.4	21
25	Functional MR Imaging in Gynecologic Cancer. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 205-222.	1.1	21
26	Design and development of a prototype endocavitary probe for high-intensity focused ultrasound delivery with integrated magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2007, 25, 548-556.	3.4	18
27	A riskâ€based approach to identifying oligometastatic disease on imaging. International Journal of Cancer, 2019, 144, 422-430.	5.1	17
28	Evaluation of diffusion models in breast cancer. Medical Physics, 2015, 42, 4833-4839.	3.0	16
29	Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth?. American Journal of Roentgenology, 2017, 209, 620-628.	2.2	16
30	Challenges in ensuring the generalizability of image quantitation methods for MRI. Medical Physics, 2022, 49, 2820-2835.	3.0	16
31	Epithelial and stromal metabolite changes in the transition from cervical intraepithelial neoplasia to cervical cancer: an in vivo 1H magnetic resonance spectroscopic imaging study with ex vivo correlation. European Radiology, 2009, 19, 2041-2048.	4.5	14
32	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	2.8	14
33	Ultrasound Shear Wave Elastography of the Normal Prostate: Interobserver Reproducibility and Comparison with Functional Magnetic Resonance Tissue Characteristics. Ultrasonic Imaging, 2018, 40, 158-170.	2.6	11
34	Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. British Journal of Cancer, 2021, 124, 1130-1137.	6.4	11
35	Spect perfusion imaging versus CT for predicting radiation injury to normal lung in lung cancer patients. British Journal of Radiology, 2019, 92, 20190184.	2.2	10
36	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper. Frontiers in Oncology, 2021, 11, 800547.	2.8	10

#	Article	IF	CITATIONS
37	Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT). Radiotherapy and Oncology, 2019, 141, 181-187.	0.6	9
38	MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study. British Journal of Radiology, 2019, 92, 20181037.	2.2	8
39	Comparison of Imaging Changes and Pain Responses in Patients with Intra- or Extraosseous Bone Metastases Treated Palliatively with Magnetic Resonance-Guided High-Intensity–Focused Ultrasound. Journal of Vascular and Interventional Radiology, 2019, 30, 1351-1360.e1.	0.5	8
40	Diffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations. Journal of Clinical Medicine, 2022, 11, 1524.	2.4	8
41	Diffusion-weighted MRI in Multicenter Trials of Breast Cancer: A Useful Measure of Tumor Response?. Radiology, 2018, 289, 628-629.	7.3	6
42	Value of diffusion-weighted imaging for monitoring tissue change during magnetic resonance-guided high-intensity focused ultrasound therapy in bone applications: an ex-vivo study. European Radiology Experimental, 2018, 2, 10.	3.4	6
43	Visualizing the autonomic and somatic innervation of the female pelvis with 3D MR neurography: a feasibility study. Acta Radiologica, 2020, 61, 1668-1676.	1.1	6
44	Distortion correction of echoâ€planar diffusionâ€weighted images of uterine cervix. Journal of Magnetic Resonance Imaging, 2016, 43, 1218-1223.	3.4	5
45	The Accuracy of ADC Measurements in Liver Is Improved by a Tailored and Computationally Efficient Local-Rigid Registration Algorithm. PLoS ONE, 2015, 10, e0132554.	2.5	4
46	Probing structure of normal and malignant prostate tissue before and after radiation therapy with luminal water fraction and diffusionâ€weighted MRI. Journal of Magnetic Resonance Imaging, 2019, 50, 619-627.	3.4	4
47	Variation of the apparent diffusion coefficient of skull bone marrow by age group, pubertal status, and gender in a pediatric population. Acta Radiologica, 2020, 61, 1240-1248.	1.1	4
48	Prediction of pelvic tumour coverage by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) from referral imaging. International Journal of Hyperthermia, 2020, 37, 1033-1045.	2.5	3
49	Feasibility of palliating recurrent gynecological tumors with MRGHIFU: comparison of symptom, quality-of-life, and imaging response in intra and extra-pelvic disease. International Journal of Hyperthermia, 2021, 38, 623-632.	2.5	3
50	Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy. BJR Open, 2019, 1, 20190029.	0.6	2
51	Estimating brain volume loss after radiation therapy in children treated for posterior fossa tumors (Corpus callosum and whole brain volume changes following radiotherapy in children). Advances in Clinical and Experimental Medicine, 2020, 29, 331-337.	1.4	1
52	Quantitative prediction of the extent of pelvic tumour ablation by magnetic resonance-guided high intensity focused ultrasound. International Journal of Hyperthermia, 2021, 38, 1111-1125.	2.5	0